This test is ideal for patients with solid tumors who want to receive additional information on their tumor sample. It can be particularly useful for patients with ovarian, peritoneal, fallopian tube, or prostate cancer to determine possible qualification for PARP inhibitors (PARPi) and adjuvant chemotherapeutics like platinum and taxanes.
This HRR/HRD test will report oncogenic changes in 15 HRR genes. It will report HRD score (high/low) by assessing the extent of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large scale transitions (LST) copy number alterations. It will list appropriate FDA recommended therapies.